Vista Pharmaceuticals Share Price Today

Vista Pharmaceuticals accepts resignation of Company Secretary Barkha Jain

Vista Pharmaceuticals accepted the resignation of Mrs. Barkha Jain as Company Secretary. Effective date for cessation is September 4, 2026. Reason cited is pursuit of alternate career opportunity outside the organisation. Disclosure made pursuant to SEBI LODR Regulation 30(2).

Vista Pharma Q1 Results: Net Loss ₹98.6 Lakh, Zero Revenue

Vista Pharmaceuticals posted a Q1FY26 net loss of ₹98.59 lakh with zero operational revenue. Lenders have classified its debt as NPAs due to servicing defaults, freezing working capital accounts. The company faces a material going-concern risk but cites ₹922.49 lakh in pending convertible warrant subscriptions to meet obligations.

Vista Pharmaceuticals reports FY26 net loss of ₹1,206.12 lakh

Vista Pharmaceuticals Limited reported a widened net loss of ₹1,206.12 lakh for FY26, with revenue from operations dropping to ₹539.95 lakh from ₹1,007.46 lakh in the previous year. The company recognised an impairment allowance of ₹821.74 lakh on trade receivables and issued convertible share warrants raising ₹307.50 lakh. Despite five consecutive years of losses and negative working capital, the Board affirmed the going concern status based on net worth and promoter support.

Vista Pharmaceuticals board meets on May 29 for FY26 results

Vista Pharmaceuticals Limited will hold a board meeting on May 29, 2026, to consider audited financial results and the audit report for the quarter and year ended March 31, 2026.

Vista Pharmaceuticals Limited Files Quarterly Compliance Certificate for Q4 FY26

Vista Pharmaceuticals Limited filed its quarterly compliance certificate under SEBI Regulation 74(5) for Q4 FY26 with BSE Limited on 14.04.2026. The certificate confirms proper handling of dematerialization processes, with registrar Aarthi Consultants Private Limited certifying completion of all required actions including certificate mutilation, record substitution, and timeline compliance within the stipulated 15-day period.

Vista Pharmaceuticals Reports Widened Q3 FY26 Loss at ₹231.94 Lakhs Amid Revenue Decline

Vista Pharmaceuticals Limited reported deteriorating financial performance for Q3 FY26 with net loss widening to ₹231.94 lakhs from ₹132.23 lakhs year-on-year, while revenue declined 5.35% to ₹241.82 lakhs. The company recognized ₹205.43 lakhs provision for Expected Credit Loss and has outstanding statutory liabilities of ₹95.48 lakhs, with results approved by the Board on February 13, 2026.